Verastem, Inc. (NASDAQ:VSTM) was founded in 2010 and is headquartered in Needham, Massachusetts, USA, with 69 full-time employees. It is a biopharmaceutical company that focuses on the development and commercialization of cancer drugs.
Verastem, Inc. (VSTM):
The Verastem, Inc. program targets focal adhesion kinase (FAK) and phosphoinositide 3-kinase (PI3K) signaling pathways. Verastem’s main FAK inhibitor is defactinib, an oral drug candidate that can be used in combination therapy with immuno-oncology drugs and other anti-cancer compounds. Verastem’s defactinib is used in phase Ib studies for the treatment of pancreatic cancer, and phase I/II clinical trials for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Verastem, Inc. is also committed to the development of duvelisib, an investigational oral treatment targeting PI3K signaling pathways, as well as attacking malignant B cells and T cells, destroying the tumor microenvironment, and helping prevent blood system cancers through the dual inhibitory effects of PI3K delta and gamma The growth and proliferation of the patient.
Verastem’s duvelisib is used for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in phase III randomized and late and mid-term clinical trials; and completed phase II study for the treatment of dual refractory inert non-Hodgkin Patients with Chikin’s lymphoma.
Verastem has license agreements with Infinity Pharmaceuticals, Inc. and Pfizer .